Irene L. Andrulis

48.7k citations

248 papers · 11.3k · 2 hit papers · h-index 54

Impact in

Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
Oncology top 0.5%
- Cancer-related Molecular Pathways

Papers in

Molecular Biology 108
- Epigenetics and DNA Methylation 17
- RNA modifications and cancer 17
Genetics 81
- BRCA gene mutations in cancer 63

Co-authors: Jay S. Wunder (44 shared papers)Frances P. O’Malley (28 shared papers)Hilmi Özçelik (29 shared papers)Dushanthi Pinnaduwage (26 shared papers)Shelley B. Bull (30 shared papers)Julia A. Knight (57 shared papers)Esther M. John (68 shared papers)Nalan Gökgöz (36 shared papers)
Journals: Breast Cancer Research and Treatment (23 papers)Journal of Clinical Oncology (13 papers)Cancer Epidemiology Biomarkers & Prevention (13 papers)Breast Cancer Research (12 papers)JNCI Journal of the National Cancer Institute (9 papers)
Partner nations: Canada United States Australia

In The Last Decade

Irene L. Andrulis

242 papers receiving 10.9k citations

Irene L. Andrulis's Hit Papers

align trajectories log scale

MADR2 Maps to 18q21 and Encodes a TGFβ–Regulated MAD–Related Protein That Is Functionally Mutated in Colorectal Carcinoma 1996 · 759 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1996 Cell
1990 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Irene L. Andrulis

Since Specialization

Citations

This map shows the geographic impact of Irene L. Andrulis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irene L. Andrulis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irene L. Andrulis more than expected).

Fields of papers citing papers by Irene L. Andrulis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irene L. Andrulis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irene L. Andrulis. The network helps show where Irene L. Andrulis may publish in the future.

Co-authors

The 25 scholars most cited alongside Irene L. Andrulis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Irene L. Andrulis Line = papers co-authored together Irene L. Andrulis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 248 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	MADR2 Maps to 18q21 and Encodes a TGFβ–Regulated MAD–Related Protein That Is Functionally Mutated in Colorectal Carcinoma Cell ·Kolja Eppert, Stephen W. Scherer, Hilmi Özçelik, Rosa Pirone, Pamela A. Hoodless, Hyeja Kim, L.-C. Tsui, Bharati Bapat, Steven Gallinger, Irene L. Andrulis, Gerald H. Thomsen, Jeffrey L. Wrana, Liliana Attisano Hit paper breakdown →	1996	759
2	Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proceedings of the National Academy of Sciences ·Kevin E. Noonan, Christian Beck, Tatyana A. Holzmayer, Janice E. Chin, Jay S. Wunder, Irene L. Andrulis, Adi F. Gazdar, Cheryl L. Willman, Barbara Griffith, Daniel D. Von Hoff, Igor B. Roninson Hit paper breakdown →	1990	675
3	EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. Journal of Clinical Oncology ·(unknown), Akira Kawai, John H. Healey, I Fligman, Paul A. Meyers, Andrew G. Huvos, William L. Gerald, S.C. Jhanwar, Pedram Argani, Cristina R. Antonescu, F. J. Pardo-Mindán, Jill P. Ginsberg, Richard B. Womer, Elizabeth R. Lawlor, Jay S. Wunder, Irene L. Andrulis, P H Sorensen, Frederic G. Barr, Marc Ladanyi	1998	416
4	The c-Myc Oncogene Directly Induces the H19 Noncoding RNA by Allele-Specific Binding to Potentiate Tumorigenesis Cancer Research ·Dalia Baršytė-Lovejoy, Suzanne K. Lau, Paul C. Boutros, Fereshteh Khosravi, Igor Jurišica, Irene L. Andrulis, Ming‐Sound Tsao, Linda Z. Penn	2006	414
5	HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy New England Journal of Medicine ·Kathleen I. Pritchard, Lois E. Shepherd, Frances P. O’Malley, Irene L. Andrulis, Dongsheng Tu, Vivien Bramwell, Mark N. Levine	2006	394
6	The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer Breast Cancer Research ·Esther M. John, John L. Hopper, Jeanne C. Beck, Julia A. Knight, Susan L. Neuhausen, Ruby T. Senie, Argyrios Ziogas, Irene L. Andrulis, Hoda Anton‐Culver, Norman F. Boyd, Saundra S. Buys, Mary B. Daly, Frances P. O’Malley, Regina M. Santella, Melissa C. Southey, Vickie L. Venne, Deon J. Venter, Dee W. West, Alice S. Whittemore, Daniela Seminara, (unknown)	2004	211
7	A mutant PTH/PTHrP type I receptor in enchondromatosis Nature Genetics ·Sevan Hopyan, Nalan Gökgöz, Raymond Poon, Robert Gensure, Chunying Yu, William G. Cole, Robert S. Bell, Harald Jüppner, Irene L. Andrulis, Jay S. Wunder, Benjamin A. Alman	2002	194
8	Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens Carcinogenesis ·Judd C. Rice, Hilmi Özçelik, Patrick Maxeiner, Irene L. Andrulis, Bernard W. Futscher	2000	190
9	Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer Proceedings of the National Academy of Sciences ·Marisa G. Ponzo, Robert Lesurf, Stephanie Petkiewicz, Frances P. O’Malley, Dushanthi Pinnaduwage, Irene L. Andrulis, Shelley B. Bull, Naila Chughtai, Dongmei Zuo, Margarita Souleimanova, David A. Russler‐Germain, Atilla Ömeroğlu, Robert D. Cardiff, Michael Hallett, Morag Park	2009	178
10	Rare variants in the ATMgene and risk of breast cancer Breast Cancer Research ·David E. Goldgar, Sue Healey, James G. Dowty, Leonard Da Silva, (unknown), Amanda B. Spurdle, Mary Beth Terry, Mary Daly, Saundra Buys, Melissa C. Southey, Irene L. Andrulis, Esther M. John, (unknown), (unknown), Kum Kum Khanna, John L. Hopper, Peter J. Oefner, Sunil R. Lakhani, Georgia Chenevix‐Trench	2011	163
11	Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy JNCI Journal of the National Cancer Institute ·F P O’Malley, Stephen Chia, Dongsheng Tu, Lois E. Shepherd, Mark N. Levine, V. Bramwell, Irene L. Andrulis, Kathleen I. Pritchard	2009	150
12	EWS-FLI1 and EWS-ERG Gene Fusions Are Associated With Similar Clinical Phenotypes in Ewing's Sarcoma Journal of Clinical Oncology ·Jill P. Ginsberg, (unknown), Marc Ladanyi, Leonard H. Wexler, Heinrich Kovar, Michael Paulussen, A. Zoubek, Barbara Dockhorn‐Dworniczak, H. Juergens, Jay S. Wunder, Irene L. Andrulis, Rajesh Malik, Poul H. Sorensen, Richard B. Womer, Frederic G. Barr	1999	143
13	Expression of the Circadian Clock Genes Pert, Per2 in Sporadic, Familial Breast Tumors Neoplasia ·Sherry L. Winter, Lucine Bosnoyan-Collins, Dushanthi Pinnaduwage, Irene L. Andrulis	2007	143
14	Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis Cancer Cell ·Wenyong Chen, Timothy K. Cooper, Cynthia A. Zahnow, Michael Overholtzer, (unknown), Marc Ladanyi, Judith E. Karp, Nalan Gökgöz, Jay S. Wunder, Irene L. Andrulis, Arnold J. Levine, Joseph L. Mankowski, Stephen B. Baylin	2004	137
15	SNP-SNP interactions in breast cancer susceptibility BMC Cancer ·Venus Onay, Laurent Briollais, Julia A. Knight, Ellen Shi, Yuanyuan Wang, Sean Wells, Hong Li, Isaac Rajendram, Irene L. Andrulis, Hilmi Özçelik	2006	134
16	Familial Posterior Fossa Brain Tumors of Infancy Secondary to Germline Mutation of the hSNF5 Gene The American Journal of Human Genetics ·Michael D. Taylor, Nalan Gökgöz, Irene L. Andrulis, Todd G. Mainprize, James M. Drake, James T. Rutka	2000	133
17	Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas Oncogene ·Jay S. Wunder, Kolja Eppert, Sarah Burrow, Nalan Gogkoz, Robert S. Bell, Irene L. Andrulis	1999	131
18	Constitutive Hedgehog Signaling in Chondrosarcoma Up-Regulates Tumor Cell Proliferation American Journal Of Pathology ·Tri Dung Tiet, Sevan Hopyan, Puviindran Nadesan, Nalan Gökgöz, Raymond Poon, Alvin C. Lin, Taiqiang Yan, Irene L. Andrulis, Benjamin A. Alman, Jay S. Wunder	2006	130
19	Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. PubMed ·Reuben Broom, Patricia A. Tang, Christine Simmons, Louise Bordeleau, Anna Marie Mulligan, Frances P. O’Malley, Naomi Miller, Irene L. Andrulis, Darren M. Brenner, Mark Clemons	2009	123
20	JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer Breast Cancer Research and Treatment ·Michael Reedijk, Dushanthi Pinnaduwage, Brendan C. Dickson, Anna Marie Mulligan, Hui Zhang, Shelley B. Bull, Frances P. O’Malley, Sean E. Egan, Irene L. Andrulis	2007	121

About Irene L. Andrulis

Irene L. Andrulis is a scholar working on Molecular Biology, Genetics, Oncology, Cancer Research and Pathology and Forensic Medicine, having authored 248 papers that have together received 11.3k indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (63 papers), Sarcoma Diagnosis and Treatment (22 papers), Breast Cancer Treatment Studies (19 papers), Cancer Genomics and Diagnostics (18 papers), Cancer Risks and Factors (18 papers), Epigenetics and DNA Methylation (17 papers), RNA modifications and cancer (17 papers) and Cancer-related Molecular Pathways (13 papers). The work is most often cited by research in Cancer Research (2.4k citations), Oncology (3.6k citations), Genetics (2.3k citations), Pathology and Forensic Medicine (1.4k citations) and Molecular Biology (5.0k citations). Irene L. Andrulis has collaborated with scholars based in Canada, United States and Australia. Frequent co-authors include Jay S. Wunder, Frances P. O’Malley, Hilmi Özçelik, Dushanthi Pinnaduwage, Shelley B. Bull, Julia A. Knight, Esther M. John, Nalan Gökgöz, Robert S. Bell and John L. Hopper. Their work appears in journals such as Breast Cancer Research and Treatment, Journal of Clinical Oncology, Cancer Epidemiology Biomarkers & Prevention, Breast Cancer Research and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Irene L. Andrulis

Impact in

Papers in i

In The Last Decade

Irene L. Andrulis

Irene L. Andrulis's Hit Papers

Peers

Countries citing papers authored by Irene L. Andrulis

Fields of papers citing papers by Irene L. Andrulis

All Works

About Irene L. Andrulis

Explore authors with similar magnitude of impact

Papers in